Post-earnings recap
Reported
Wed, Feb 8, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which led to a slight increase in stock price by 0.42%. The absence of revenue details leaves some uncertainty, but management's positive tone suggests confidence in their ongoing projects. Investors may view the EPS beat as a sign of progress, even without additional guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.32 | N/A | +2.44% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results despite not providing revenue figures. They emphasized their commitment to pipeline development.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.